Pharming Group N.V. (PHAR) stock
Close on Nov 11, 2026Market cap $940.25MP/E 335.0Yield –
Pharming Group N.V. grew revenue 26.6% to $376.13M over fiscal 2025. Free cash flow was $53.96M. At the latest close the market valued the company at $940.25M, 335.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $940.25M
- P/E ratio
- 335.0
- Price to sales
- 2.50
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 5.74%
Fundamentals
- Revenue
- $376.13M
- Net income
- $2.85M
- EPS, diluted
- $0.00
- Free cash flow
- $53.96M
Trading
- Previous close
- $13.22
- Open
- $12.94
- Day's range
- $12.92 – $13.40
- Volume
- 12,767
- Average volume (20 days)
- 17,161
- Beta (5 years)
- 0.56
- 52-week range
- $9.11 – $21.34
- RSI (14 days)
- 72.7
- Volatility (1 year)
- 61.1%
- Relative volume
- 0.62×
- WACC
- 7.7%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PHAR | S&P 500 | Difference | PHAR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +36.9% | -2.4% | +39.3 pts | ||
| 3 months | +9.6% | -1.2% | +10.7 pts | ||
| Year to date | -24.2% | +12.3% | −36.5 pts | ||
| 1 year | -15.1% | +12.4% | −27.6 pts | ||
| 3 years | +21.7% | +78.8% | −57.1 pts | +6.8% | +21.4% |
| 5 years | +45.7% | +75.2% | −29.5 pts | +7.8% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About Pharming
Pharmaceutical Preparations
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes therapies for rare and ultra-rare diseases with significant unmet medical needs. The company focuses primarily on genetic and immunological conditions. Its commercial portfolio includes RUCONEST, an intravenous recombinant C1 esterase inhibitor replacement therapy for acute hereditary angioedema attacks in adult and adolescent patients, and Joenja (leniolisib), an oral targeted inhibitor for activated phosphoinositide 3-kinase delta syndrome. Pharming provides its therapies to rare disease patients, specialist healthcare providers, and clinical communities.
Company profile, executives and historyPharming stock: common questions
What is Pharming's stock price?
PHAR closed at $13.40 on Nov 11, 2026, up 1.36% on the day. Over the past 52 weeks it traded between $9.11 and $21.34.
What is Pharming's market cap?
Pharming was worth $940.25M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PHAR's P/E ratio?
PHAR trades at 335.0 times earnings, based on diluted earnings per share of $0.00 over fiscal 2025.
How much revenue does Pharming make?
Pharming reported revenue of $376.13M for fiscal 2025, up 26.6% from a year earlier.
Does Pharming pay a dividend?
No. Pharming has not paid a cash dividend over the last twelve months.
How has PHAR stock performed over the past year?
Including dividends, PHAR returned -15.1% over the past year, against +12.4% for the S&P 500.
Who are Pharming's competitors?
Companies most similar to Pharming by business, industry and size include MIRM, TVTX, RARE, XERS, ZLAB.
See a number that looks wrong?